The cofounder and chief product development officer of Zevra Therapeutics talked about the phase 1 clinical trial of KP1077 for narcolepsy and potentially using it to treat other conditions. [WATCH TIME: 5 minutes]
Christal Mickle
Advertisement
Cofounder and chief product development officer of Zevra Therapeutics.
Articles by Christal Mickle
Advertisement
Latest Updated Articles
Expanding KP1077’s Clinical Program to Address Narcolepsy and Other Conditions: Christal MicklePublished: April 21st 2023 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Doxecitine and Doxribtimine Combination Therapy as First Treatment for Thymidine Kinase 2 Deficiency
2
Exploring Long-Term Efficacy of Inebilizumab in Phase 3 Myasthenia Gravis Trial: Richard Nowak, MD, MS
3
Alexander Gold, MD, on Adrabetadex’s Impact in Infantile-Onset Niemann-Pick C
4
Showcasing Sustained Benefits in Myasthenia Gravis Research at AANEM 2025: Kimberly Moran, PhD, MBA
5
